Related Experiment Videos
Peptide-based vaccines for cancer immunotherapy
Joeli A Brinkman1, Steven C Fausch, Jeffrey S Weber
1University of Southern California, 1501 San Pablo Street, ZNI 245, MC 2821, Los Angeles, CA 90089-2821, USA.
Expert Opinion on Biological Therapy
|March 5, 2004
Summary
Cancer immunotherapy using peptide vaccines shows low toxicity but inconsistent clinical responses. Ongoing research into improved strategies like adjuvants and dendritic cells aims to enhance efficacy for better cancer treatment outcomes.
Area of Science:
- Immunology
- Oncology
- Vaccine Development
Background:
- Peptide vaccines targeting tumour-associated antigens are a key strategy in cancer immunotherapy.
- These vaccines aim to stimulate T cell responses via major histocompatibility complex (MHC) class I or II molecules.
Purpose of the Study:
- To review the current status and challenges of peptide-based cancer vaccines.
- To identify areas for improvement in peptide vaccination strategies.
Main Methods:
- Analysis of clinical trial data for peptide vaccination in various cancer types.
- Evaluation of discrepancies between in vitro and clinical responses.
- Review of emerging strategies to enhance vaccine efficacy.
Main Results:
- Peptide vaccination generally demonstrates a favorable safety profile with minimal toxicity.
- Significant variability exists between laboratory findings and actual clinical efficacy.
- The field is evolving, making definitive conclusions on efficacy challenging.
Conclusions:
- Peptide vaccination is a safe approach for cancer immunotherapy but requires optimization.
- Future research focusing on enhanced delivery, adjuvants, and combination therapies holds promise.
- Further investigation is needed to overcome the gap between preclinical and clinical outcomes.